Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Withdrawn 1Unknown 1Not yet recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 685Breast Neoplasms 584Neoplasms 468Colorectal Neoplasms 298Prostatic Neoplasms 262Neoplasm Metastasis 256Melanoma 241Ovarian Neoplasms 228Recurrence 216Lung Neoplasms 203Multiple Myeloma 195Lymphoma, Non-Hodgkin 155Pancreatic Neoplasms 154Leukemia, Myeloid, Acute 141Carcinoma, Hepatocellular 141Stomach Neoplasms 137Lymphoma 131Carcinoma, Renal Cell 128Glioblastoma 118Head and Neck Neoplasms 112Squamous Cell Carcinoma of Head and Neck 111Lymphoma, Follicular 106Leukemia, Lymphocytic, Chronic, B-Cell 99Lymphoma, Large B-Cell, Diffuse 96Leukemia 96Small Cell Lung Carcinoma 95Brain Neoplasms 91Carcinoma 82Uterine Cervical Neoplasms 76Triple Negative Breast Neoplasms 72

Interventions

pembrolizumab 1HLX07 1Cetuximab 1CCT239065 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × CRC × Clear all
NCT07511972 2026-04-06

Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

NGM Biopharmaceuticals, Inc

Phase 2 Withdrawn

CRC

NCT04984369 2023-08-21

The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment

Shanghai Henlius Biotech

Phase 2 Unknown
50 enrolled

CRC

NCT05239650 2022-05-03

Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC

Shanghai Henlius Biotech

Phase 2 Not yet recruiting
50 enrolled

CRC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡